Krystal Biotech, Inc. (KRYS) Stock
1 member of Congress disclosed 1 trade in KRYS since 2022: 1 purchase and 0 sales, most recently Christopher L. Jacobs (purchase, Dec 12, 2022). 4 of the hedge funds AlphaScala tracks reported KRYS in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $22.18M. Company insiders reported 0 open-market buys and 34 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
Which members of Congress traded Krystal Biotech, Inc. (KRYS)?
Most recent: Christopher L. Jacobs (purchase, Dec 12, 2022); records start Dec 12, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-12-12 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all KRYS political trades →Which hedge funds own KRYS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 60K | $22.18M | +522% |
| Bridgewater Associates Ray Dalio | 54K | $20.25M | +18% |
| Hussman Investment Trust John Hussman | 4K | $1.40M | NEW |
| Citadel Ken Griffin | 3K | $1.01M | -0% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Krystal Biotech, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 520 | $184K |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 2.0K | $721K |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 3.3K | $1.2M |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 4.0K | $1.4M |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 3.1K | $1.1M |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 3.4K | $1.2M |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 2.3K | $817K |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 1.2K | $439K |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 2.0K | $729K |
| Sep 4, 26 | Krishnan Krish S | President and CEO | SELL | 573 | $208K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →KRYS price chart
Powered by TradingViewWhat does Krystal Biotech, Inc. do?
Krystal Biotech Inc. is a biotechnology company primarily focused on developing and commercializing gene therapy products for patients with rare dermatological conditions. Its innovative platform harnesses gene delivery technology to address unmet medical needs by developing a pipeline of products aimed at treating genetic skin diseases. Krystal Biotech’s key asset is its proprietary STAR-D platform, which allows for the non-viral delivery of therapeutic genes directly into the skin. This platform exemplifies the company's commitment to deploying cutting-edge science to improve patient outcomes. The company primarily impacts the healthcare and biotechnology sectors, seeking to revolutionize treatments for genetic disorders. Incorporated in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a significant role in advancing therapeutic options within the niche market of dermatological diseases, thereby positioning itself as a transformative player in gene therapy and medical research.